Proteoglycan Metabolism During Cardiac Valve Development and Disease
心脏瓣膜发育和疾病期间的蛋白多糖代谢
基本信息
- 批准号:10543104
- 负责人:
- 金额:$ 53.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:ADAMTSActive SitesAdultAffectAmino AcidsAneurysmAortaAortic RuptureArteriesBehaviorBlood VesselsBlood flowCardiacCardiovascular systemCell LineageCellsCoronary arteryDataDefectDegenerative polyarthritisDevelopmentDiseaseElasticityEndotheliumEventExhibitsExtracellular MatrixFetusHeart ValvesHumanIndividualInvestigationLabelLasersMesenchymalMetabolismModelingMolecularMorphologyMusMutationMyocardialNeural CrestOrganPatientsPatternPenetrancePharmaceutical PreparationsPregnant WomenPrevalenceProteoglycanPublishingReportingReproducibilityResearchRisk FactorsRoleRuptureSignal TransductionStromelysin 1Sudden DeathTestingTherapeuticTissuesaggrecanaortic valveaortic valve disorderascending aortabicuspid aortic valvecell behaviorcomorbiditycongenital heart disorderdesignexperimental studyin vivoinhibitorinsightmalformationmouse modelnew therapeutic targetpreventside effecttargeted sequencingtherapeutic targettherapeutically effectivetranscriptome sequencingversican
项目摘要
Summary: Approximately 1.5% of individuals have a Bicuspid Aortic Valve (BAV) that can result in insufficient
blood flow and organ damage (1, 2). A BAV is also an independent risk factor for ascending aortic wall
complications that can lead to rupture and sudden death. However, the cell and molecular basis for the BAV is
unknown. Even basic aspects of BAV formation are undefined due to contributions from multiple cell lineages
and a lack of highly penetrant viable BAV mouse models. Dysfunctional aortic valves exhibit massive
accumulation of the extracellular matrix (ECM) proteoglycans versican (Vcan) and aggrecan (Acan) (3-7) but the
origin and consequence of excess proteoglycans is largely unknown. Since proteoglycans are highly stable,
abundance is regulated primarily by proteolytic degradation which led us to investigate a role for proteoglycan
cleavage. We discovered that loss of a single ECM proteoglycanase, Adamts5, results in enlarged aortic valves
with ascending aortopathies (100%). These defects co-localize with substantial increases in Vcan and Acan in
the affected tissues (8-10) that mirror the human condition. Mechanistically, in Adamts5-/- aortic valve primordia
with excess Vcan there is a reduction of pSmad2, and when Smad2 is reduced further by generating Adamts5-/-
;Smad2+/- mice, there is a high penetrance of BAV (75%), much higher than seen in other mouse BAV models.
The objective of this proposal is to utilize the viable Adamts5-/-;Smad2+/- mice that exhibit a high percentage of
BAV, to define morphological events, cell behaviors and factors that when disrupted contribute to BAV formation.
Since excess Vcan is a hallmark of dysfunctional and diseased valves, use of a model with mutations that impact
the control of Vcan content, may shed light on how proteoglycan metabolism is regulated in development and
may also give insight into disease. Experiments test the hypothesis that ECM Vcan cleavage coordinates
mesenchymal cell behaviors and myocardial cell contributions that are required for the tricuspid morphology of
aortic valves. The hypothesis is tested in two aims: Aim 1 tests the impact of altered Vcan cleavage on
mesenchymal cell lineage behaviors that are required for aortic valve formation. Our preliminary data show that
loss of Vcan cleaved fragments and excess intact Vcan, disrupted lineage-specific patterning in the developing
aortic valves of the BAV Adamts5-/-;Smad2+/-mice. A combination of ex vivo, and in vivo approaches will decipher
the lineage-specific cell behaviors, and guidance factors that are dependent on Vcan cleavage and to prevent
BAV. Although dogma states that valve cusps arise from mesenchymal cells, Aim 2 investigates the
consequence of excess Vcan on the myocardial cell lineage contributions to the developing aortic valve in
Adamts5-/-;Smad2+/- mice and other murine models of BAV. Our preliminary data show myocardial lineage
expression of Adamts5 is required to clear Vcan-rich ECM and to form the non-coronary cusp of the aortic valve.
Due to the emerging prevalence of excess Vcan in BAV, the investigation into ECM turnover will allow insight
into the molecular and cellular origins of aortic valve diseases, which may lead to therapeutic advances.
总结:大约1.5%的人患有二叶式主动脉瓣(BAV),这可能导致
血流和器官损伤(1,2)。BAV也是升主动脉壁的独立危险因素
可能导致破裂和猝死的并发症。然而,BAV的细胞和分子基础是
未知由于多种细胞谱系的贡献,甚至BAV形成的基本方面也不确定
以及缺乏高度渗透的存活BAV小鼠模型。功能障碍的主动脉瓣
细胞外基质(ECM)蛋白聚糖多功能蛋白聚糖(Vcan)和聚集蛋白聚糖(Acan)的积累(3-7),但
过量蛋白聚糖的起源和后果在很大程度上是未知的。由于蛋白聚糖是高度稳定的,
蛋白多糖的丰度主要受蛋白水解降解的调节,这使我们研究了蛋白多糖
乳沟我们发现单一ECM蛋白聚糖酶Adamts 5的缺失导致主动脉瓣扩大
上升性脊髓炎(100%)。这些缺陷与Vcan和Acan的显著增加共定位,
反映人体状况的受影响组织(8-10)。从机制上讲,在Adamts 5-/-主动脉瓣原基中
当Vcan过量时,pSmad 2减少,当Smad 2通过产生Adamts 5-/-
在Smad 2 +/-小鼠中,存在高BAV检出率(75%),远高于在其它小鼠BAV模型中所见。
本提案的目的是利用表现出高百分比的Adamts 5-/-; Smad 2 +/-小鼠。
BAV,以定义形态学事件、细胞行为和当被破坏时有助于BAV形成的因素。
由于过量Vcan是功能障碍和患病瓣膜的标志,因此使用具有影响
Vcan含量的控制,可以揭示蛋白多糖代谢在发育中是如何调节的,
也能让我们了解疾病实验验证了ECM Vcan切割协调
间充质细胞的行为和心肌细胞的贡献是三尖瓣形态所需的,
主动脉瓣在两个目的中测试该假设:目的1测试改变的Vcan切割对Vcan细胞的影响。
间充质细胞谱系的行为所需的主动脉瓣形成。初步数据显示,
Vcan切割片段的丢失和过量的完整Vcan,破坏了发育中的谱系特异性模式,
BAV Adamts 5-/-; Smad 2 +/-小鼠的主动脉瓣。体外和体内方法的结合将破译
谱系特异性细胞行为,以及依赖于Vcan切割和阻止Vcan切割的指导因子。
BAV。尽管教条指出瓣膜尖来自间充质细胞,但目标2研究了
结果过量的Vcan对心肌细胞谱系的贡献,发展主动脉瓣,
Adamts 5-/-; Smad 2 +/-小鼠和其他BAV鼠模型。我们的初步数据显示心肌谱系
需要Adamts 5的表达来清除富含Vcan的ECM并形成主动脉瓣的非冠状尖。
由于BAV中Vcan过量的流行,对ECM周转的研究将使我们了解
主动脉瓣疾病的分子和细胞起源,这可能导致治疗进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christine Bruins Kern其他文献
Christine Bruins Kern的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christine Bruins Kern', 18)}}的其他基金
Proteoglycan Metabolism During Cardiac Valve Development and Disease
心脏瓣膜发育和疾病期间的蛋白多糖代谢
- 批准号:
10341254 - 财政年份:2022
- 资助金额:
$ 53.45万 - 项目类别:
Proteoglycan Regulation During Cardiac Valve Development and Homeostasis
心脏瓣膜发育和稳态过程中的蛋白多糖调节
- 批准号:
9302824 - 财政年份:2014
- 资助金额:
$ 53.45万 - 项目类别:
Proteoglycan Regulation During Cardiac Valve Development and Homeostasis
心脏瓣膜发育和稳态过程中的蛋白多糖调节
- 批准号:
8760823 - 财政年份:2014
- 资助金额:
$ 53.45万 - 项目类别:
PRRX REGULATION OF EXTRACELLULAR MATRIX GENES DURING CRANIOFACIAL DEVELOPMENT
PRRX 对颅面发育过程中细胞外基质基因的调控
- 批准号:
8360490 - 财政年份:2011
- 资助金额:
$ 53.45万 - 项目类别:
MATRIX METALLOPROTEINASE CLEAVAGE OF VERSICAN IN CARDIAC OUTLET REMODELING
心脏出口重塑中 VERSICAN 的基质金属蛋白酶裂解
- 批准号:
8167796 - 财政年份:2010
- 资助金额:
$ 53.45万 - 项目类别:
EXAMINATION OF CIS ELEMENTS OF BETA GLOBIN GENES
β 珠蛋白基因的 CIS 元件检查
- 批准号:
2135801 - 财政年份:1994
- 资助金额:
$ 53.45万 - 项目类别:
EXAMINATION OF CIS ELEMENTS OF HUMAN BETA GLOBIN GENES
人类 β 珠蛋白基因的 CIS 元件的检查
- 批准号:
2135800 - 财政年份:1993
- 资助金额:
$ 53.45万 - 项目类别:
相似海外基金
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334970 - 财政年份:2024
- 资助金额:
$ 53.45万 - 项目类别:
Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
- 批准号:
2400195 - 财政年份:2024
- 资助金额:
$ 53.45万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334969 - 财政年份:2024
- 资助金额:
$ 53.45万 - 项目类别:
Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
- 批准号:
23K04919 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
- 批准号:
22KJ2957 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
- 批准号:
23K04494 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
- 批准号:
23K13831 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
- 批准号:
2238379 - 财政年份:2023
- 资助金额:
$ 53.45万 - 项目类别:
Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
- 批准号:
2154399 - 财政年份:2022
- 资助金额:
$ 53.45万 - 项目类别:
Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
- 批准号:
RGPIN-2019-06633 - 财政年份:2022
- 资助金额:
$ 53.45万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




